Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistiVisitDoc sold compounded semaglutide products online with false or misleading claims that implied they were equivalent to FDA-approved drugs like Wegovy and Ozempic, violating the Federal Food, Drug, and Cosmetic Act sections 502(a) and 502(bb). Specifically, the company claimed their compounded semaglutide had "the same active ingredients" as approved products and were "clinically validated," despite compounded drugs not being FDA-approved. These misbranded products were unlawfully introduced into interstate commerce through the company's website.